Is oral terbinafine safe for a breastfeeding mother with a history of fatty liver disease who is otherwise healthy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Terbinafine Use in Breastfeeding with History of Fatty Liver

Terbinafine should be avoided in breastfeeding mothers, and is not recommended in patients with a history of fatty liver disease, even if currently stable and otherwise healthy.

Breastfeeding Considerations

The FDA drug label explicitly states that "treatment with terbinafine is not recommended in nursing mothers" 1. This recommendation is based on pharmacokinetic data showing that terbinafine is present in breast milk at a milk-to-plasma ratio of 7:1, meaning the drug concentrates significantly in breast milk 1. While one guideline notes that "terbinafine passes into breast milk, and this could have an effect on a nursing baby" 2, the official FDA labeling takes a more definitive stance against its use during lactation.

The concern is not merely theoretical—the high lipophilicity of terbinafine (which allows excellent tissue penetration for treating fungal infections) also facilitates transfer into breast milk, potentially exposing the infant to substantial drug levels 3.

Fatty Liver Disease Considerations

Systemic terbinafine is explicitly not recommended in patients with active or chronic liver disease 3. The British Association of Dermatologists guidelines (2014) clearly state: "systemic terbinafine is not recommended in patients with active or chronic liver disease" 3. This applies even to non-alcoholic fatty liver disease (NAFLD), which represents chronic liver disease.

Key hepatotoxicity concerns:

  • Rare but serious hepatotoxicity has been reported, occurring "usually in patients with pre-existing liver disease" 3
  • The FDA drug label warns that "cases of liver failure, some leading to liver transplant or death, have occurred" in individuals both with and without pre-existing liver disease 1
  • Baseline liver function tests and complete blood count are recommended in patients with hepatic abnormalities or risk factors 3
  • Terbinafine clearance is decreased in patients with severe liver disease 3

Important caveat:

While one case report documented safe use of terbinafine in a patient with stable autoimmune hepatitis 4, this was done with extensive precautions including hepatologist consultation, limiting treatment to <6 weeks, and close monitoring. This represents an exceptional circumstance rather than standard practice, and the patient had a different liver condition than fatty liver disease.

Clinical Algorithm for This Patient

Given both breastfeeding status AND history of fatty liver:

  1. Do not prescribe terbinafine - both conditions represent relative to absolute contraindications

  2. Alternative approaches:

    • Delay treatment until after breastfeeding is completed (onychomycosis treatment can be safely postponed)
    • Consider topical antifungal therapy alone if the condition requires treatment (though less effective for onychomycosis)
    • If the fungal infection is severe and requires systemic therapy, consider griseofulvin as an alternative, though it also has limitations in breastfeeding
  3. If treatment absolutely cannot be delayed:

    • Patient must discontinue breastfeeding before starting terbinafine
    • Obtain baseline liver function tests and complete blood count
    • Consider hepatology consultation given fatty liver history
    • Monitor liver enzymes during treatment
    • Educate patient on signs of hepatotoxicity (persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, pale stools)

Additional Safety Considerations

Beyond hepatotoxicity and breastfeeding concerns, patients should be counseled about:

  • Permanent taste disturbance (rare but can be severe and irreversible) 3, 1
  • Smell disturbance including permanent loss of smell 1
  • Rare serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) 3, 1

The combination of breastfeeding and pre-existing liver disease makes terbinafine particularly unsuitable for this patient, and alternative management strategies should be pursued.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.